Y-mAbs Therapeutics, Inc. (YMAB)
Largest Insider Buys in Sector
YMAB Stock Price History Chart
YMAB Stock Performance
About Y-mAbs Therapeutics, Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Insider Activity of Y-mAbs Therapeutics, Inc.
Over the last 12 months, insiders at Y-mAbs Therapeutics, Inc. have bought $3.53M and sold $3.88M worth of Y-mAbs Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Y-mAbs Therapeutics, Inc. have bought $2.16M and sold $31.86M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Wedell-Wedellsborg Johan (director) — $1.77M. WG Biotech ApS (director) — $1.77M.
The last purchase of 109,318 shares for transaction amount of $765,075 was made by WG Biotech ApS (director) on 2023‑12‑11.
List of Insider Buy and Sell Transactions, Y-mAbs Therapeutics, Inc.
| 2024-06-11 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 35,000 0.0797% | $12.00 | $420,000 | -0.08% | |
| 2024-06-10 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 35,000 0.0795% | $12.03 | $421,050 | -0.54% | |
| 2024-06-10 | Sale | Ber Gerard | director | 722 0.0016% | $12.00 | $8,664 | -0.54% | |
| 2024-05-31 | Sale | Kruse Bo | EVP, CFO, SECRY & TREAS. | 31,371 0.0713% | $12.07 | $378,648 | -0.41% | |
| 2024-05-30 | Sale | Kruse Bo | EVP, CFO, SECRY & TREAS. | 28,629 0.0653% | $12.03 | $344,407 | +0.08% | |
| 2024-05-23 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 7,351 0.0176% | $13.00 | $95,563 | -2.74% | |
| 2024-05-21 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 25,000 0.0544% | $12.00 | $300,000 | -3.90% | |
| 2024-03-05 | Sale | Gad Thomas | CHIEF BUSINESS OFFICER | 3,900 0.0088% | $16.44 | $64,116 | -13.10% | |
| 2024-03-05 | Sale | Smith Susan Laura | SVP & CHIEF COMMERCIAL OFFICER | 1,682 0.0038% | $16.55 | $27,837 | -13.10% | |
| 2024-03-05 | Sale | Rajah Vignesh | SVP & CHIEF MEDICAL OFFICER | 1,711 0.0039% | $16.53 | $28,283 | -13.10% | |
| 2023-12-15 | Sale | Gad Thomas | Chief Business Officer | 50,000 0.1144% | $6.61 | $330,500 | +98.95% | |
| 2023-12-14 | Sale | Gad Thomas | Chief Business Officer | 50,000 0.113% | $6.83 | $341,500 | +91.25% | |
| 2023-12-13 | Sale | Gad Thomas | Chief Business Officer | 50,000 0.1109% | $6.58 | $329,000 | +90.95% | |
| 2023-12-11 | WG Biotech ApS | director | 109,318 0.2637% | $7.00 | $765,075 | +95.93% | ||
| 2023-12-11 | Wedell-Wedellsborg Johan | director | 109,318 0.2637% | $7.00 | $765,075 | +95.93% | ||
| 2023-12-08 | WG Biotech ApS | director | 18,503 0.0418% | $6.99 | $129,379 | +82.93% | ||
| 2023-12-08 | Wedell-Wedellsborg Johan | director | 18,503 0.0418% | $6.99 | $129,379 | +82.93% | ||
| 2023-12-07 | WG Biotech ApS | director | 6,183 0.0135% | $6.50 | $40,190 | +89.99% | ||
| 2023-12-07 | Wedell-Wedellsborg Johan | director | 6,183 0.0135% | $6.50 | $40,190 | +89.99% | ||
| 2023-11-29 | WG Biotech ApS | director | 51,837 0.1191% | $5.97 | $309,477 | +113.57% |
Insider Historical Profitability
| WG Biotech ApS | director | 4559233 10.4518% | $12.03 | 7 | 8 | <0.0001% |
| Wedell-Wedellsborg Johan | director | 4559233 10.4518% | $12.03 | 7 | 17 | <0.0001% |
| Gad Thomas | Chief Business Officer | 162681 0.6076% | $12.03 | 0 | 104 | |
| Kruse Bo | EVP, CFO, Secretary & Treas. | 210877 0.4151% | $12.03 | 0 | 23 | |
| Smith Susan Laura | SVP & CHIEF COMMERCIAL OFFICER | 33918 0.0775% | $12.03 | 0 | 1 | |
| Rajah Vignesh | SVP & CMO | 33889 0.0098% | $12.03 | 4 | 1 | <0.0001% |
| Ber Gerard | director | 1608 0.0037% | $12.03 | 0 | 1 | |
| HEALY JAMES | director | 2194278 5.0303% | $12.03 | 2 | 0 | +8.58% |
| TYAGI ASHU | director | 1392740 3.1928% | $12.03 | 1 | 0 | <0.0001% |
| Moller-San Pedro Claus Juan | Chief Executive Officer | 607303 1.3922% | $12.03 | 2 | 4 | +58.04% |
| Ahmed Mahiuddin | Sr. VP and CSO | 150000 0.3439% | $12.03 | 0 | 5 | |
| GILL DAVID N | director | 0 0% | $12.03 | 0 | 3 | |
| Raskin Gregory S | director | 0 0% | $12.03 | 0 | 1 |
Institutional Investor Ownership
| BlackRock | $46.46M | 6.51 | 2.86M | -2.05% | -$972,722.03 | <0.01 | |
| Paradigm BioCapital Advisors LP | $36.32M | 5.09 | 2.23M | New | +$36.32M | 1.32 | |
| Sofinnova | $35.68M | 5 | 2.19M | 0% | +$0 | 0.07 | |
| The Vanguard Group | $33.65M | 4.72 | 2.07M | -7.79% | -$2.84M | <0.01 | |
| Polar Capital | $29.77M | 4.17 | 1.83M | -10.98% | -$3.67M | 0.17 | |
| Point72 Asset Management | $24.83M | 3.48 | 1.53M | New | +$24.83M | 0.05 | |
| D. E. Shaw & Co. | $17.37M | 2.43 | 1.07M | -19.31% | -$4.16M | 0.02 | |
| State Street | $12.21M | 1.71 | 751,073 | -1.37% | -$170,063.34 | <0.01 | |
| Geode Capital Management | $12.08M | 1.69 | 742,749 | +0.57% | +$68,316.47 | <0.01 | |
| Acadian Asset Management | $9.79M | 1.37 | 602,314 | -24.93% | -$3.25M | 0.03 | |
| Caligan Partners LP | $9.55M | 1.34 | 587,276 | -43.98% | -$7.5M | 2.52 | |
| Soleus Capital Management, L.P. | $9.28M | 1.3 | 570,982 | +263.26% | +$6.73M | 0.09 | |
| Dimensional Fund Advisors | $6.81M | 0.95 | 418,699 | +33.73% | +$1.72M | <0.01 | |
| Goldman Sachs | $5.94M | 0.83 | 365,536 | -8.14% | -$527,067.78 | <0.01 | |
| Boothbay Fund Management LLC | $5.63M | 0.79 | 346,511 | -50.08% | -$5.65M | 0.19 | |
| Northern Trust | $5.23M | 0.73 | 321,715 | -1.14% | -$60,552.24 | <0.01 | |
| Millennium Management LLC | $4.59M | 0.64 | 282,551 | +1,241.58% | +$4.25M | <0.01 | |
| Nuveen | $4.35M | 0.61 | 267,730 | -33.06% | -$2.15M | <0.01 | |
| Charles Schwab | $4.07M | 0.57 | 250,225 | +1.1% | +$44,210.94 | <0.01 | |
| Connor Clark & Lunn Investment Management Ltd | $3.29M | 0.46 | 202,074 | +18.86% | +$521,474.42 | 0.01 | |
| Morgan Stanley | $3.06M | 0.43 | 188,097 | -23.27% | -$927,600.41 | <0.0001 | |
| Jacobs Levy Equity Management | $2.5M | 0.35 | 154,016 | -39.1% | -$1.61M | 0.01 | |
| Wellington Management Company | $2.38M | 0.33 | 146,303 | New | +$2.38M | <0.0001 | |
| Two Sigma Advisers LP | $2.12M | 0.3 | 130,400 | -20.97% | -$562,596.00 | <0.01 | |
| Los Angeles Capital Management LLC | $2.07M | 0.29 | 127,551 | -64.22% | -$3.72M | 0.01 | |
| Citadel Advisors LLC | $1.92M | 0.27 | 118,301 | -13.96% | -$312,175.70 | <0.01 | |
| Renaissance Technologies | $1.88M | 0.26 | 115,300 | -34.04% | -$967,584.56 | <0.01 | |
| BNY Mellon | $1.82M | 0.26 | 111,980 | -6.66% | -$129,868.56 | <0.0001 | |
| Two Sigma | $1.7M | 0.24 | 104,302 | +68.67% | +$690,448.57 | <0.01 | |
| Jane Street Capital | $1.63M | 0.23 | 100,518 | +211.32% | +$1.11M | <0.01 | |
| Rice Hall James & Associates, LLC | $1.4M | 0.2 | 86,146 | +0.74% | +$10,292.58 | 0.09 | |
| Massachusetts Financial Services Co Ma | $1.29M | 0.18 | 79,442 | -0.22% | -$2,845.50 | <0.0001 | |
| Cubist Systematic Strategies | $1.26M | 0.18 | 77,786 | +109.6% | +$661,359.05 | 0.01 | |
| Campbell Co Investment Adviser Llc | $1.24M | 0.17 | 76,440 | -7.22% | -$96,763.23 | 0.1 | |
| Bridgeway Capital Management | $1.07M | 0.15 | 65,600 | -31.38% | -$487,800.00 | 0.02 | |
| Prudential Financial | $1.06M | 0.15 | 65,160 | -42.67% | -$788,447.70 | <0.01 | |
| AllianceBernstein | $1.01M | 0.14 | 61,920 | -1.29% | -$13,170.60 | <0.0001 | |
| RhumbLine Advisers | $897,932.00 | 0.13 | 55,224 | +2.24% | +$19,690.63 | <0.01 | |
| Squarepoint Ops LLC | $844,496.00 | 0.12 | 51,937 | New | +$844,496.00 | <0.01 | |
| American Century Investments | $744,692.00 | 0.1 | 45,799 | +61.02% | +$282,192.40 | <0.0001 | |
| Federated Hermes | $724,627.00 | 0.1 | 44,565 | +0.2% | +$1,479.66 | <0.01 | |
| AQR Capital | $615,294.00 | 0.09 | 37,841 | New | +$615,294.00 | <0.01 | |
| UBS | $610,514.00 | 0.09 | 37,547 | +2.19% | +$13,056.77 | <0.0001 | |
| Ziegler FAMCO Hedged Equity Fund | $576,596.00 | 0.08 | 35,461 | New | +$576,596.00 | <0.01 | |
| State of Wisconsin Investment Board | $569,149.00 | 0.08 | 35,003 | -54.48% | -$681,294.26 | <0.01 | |
| Ohio Strs | $570,000.00 | 0.08 | 35,100 | -55.4% | -$708,034.19 | <0.01 | |
| Boston Partners | $555,520.00 | 0.08 | 34,165 | New | +$555,520.00 | <0.01 | |
| Franklin Templeton Investments | $536,271.00 | 0.08 | 32,981 | +109.56% | +$280,371.15 | <0.0001 | |
| JPMorgan Chase | $506,791.00 | 0.07 | 31,168 | -24.65% | -$165,786.74 | <0.0001 | |
| Fidelity Investments | $454,727.00 | 0.06 | 27,966 | -24.09% | -$144,323.71 | <0.0001 |